Connect Biopharma Holdings Ltd Cash Flow Conversion Efficiency
Connect Biopharma Holdings Ltd cash flow conversion efficiency. Based on the latest financial reports, Connect Biopharma Holdings Ltd (CNTB) has a cash flow conversion efficiency ratio of -1.189x as of June 2026. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow ($-31.93 Million) by net assets ($26.86 Million). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations.
Cash Flow Conversion Efficiency of Connect Biopharma Holdings Ltd (2018–2025)
Cash flow conversion efficiency of Connect Biopharma Holdings Ltd from 2018 to 2025. This chart illustrates how Connect Biopharma Holdings Ltd's cash flow conversion efficiency has evolved over time, based on yearly financial data. View CNTB stock price and chart for real-time trading data and today's change.
Connect Biopharma Holdings Ltd Cash Flow Conversion Ratio Explained
Connect Biopharma Holdings Ltd cash flow conversion ratio divides operating cash flow by net assets, so a higher ratio means more cash generated from each unit of shareholder equity.
Connect Biopharma Holdings Ltd Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Connect Biopharma Holdings Ltd ranked by their cash flow conversion efficiency. Also see how much is Connect Biopharma Holdings Ltd worth for the company's overall valuation and market capitalisation.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Promateris SA
RO:PPL
|
N/A |
|
Maison Antoine Baud Société Anonyme
PA:MLMAB
|
N/A |
|
Kalaris Therapeutics, Inc.
NASDAQ:KLRS
|
-0.195x |
|
Tritax Big Box REIT plc
LSE:BBOX
|
0.010x |
|
Sinil Pharmaceutical Co. Ltd
KQ:012790
|
0.017x |
|
Sietel Ltd
AU:SSL
|
-0.001x |
|
Abrdn PLC
LSE:ABDN
|
0.044x |
|
Riverview Rubber Estates Bhd
KLSE:2542
|
0.009x |
Annual Cash Flow Conversion Efficiency for Connect Biopharma Holdings Ltd (2018–2025)
The table below shows the annual cash flow conversion efficiency of Connect Biopharma Holdings Ltd from 2018 to 2025. Review Connect Biopharma Holdings Ltd (CNTB) flexibility index to assess the company's free cash flow relative to its total liabilities.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2025-12-31 | $41.98 Million | $-51.21 Million | -1.220x | -376.12% |
| 2024-12-31 | $92.17 Million | $-23.61 Million | -0.256x | +45.75% |
| 2023-12-31 | $101.50 Million | $-47.93 Million | -0.472x | +25.08% |
| 2022-12-31 | $157.49 Million | $-99.27 Million | -0.630x | +68.51% |
| 2021-12-31 | $272.26 Million | $-544.93 Million | -2.002x | -287.84% |
| 2020-12-31 | $-24.03 Million | $-25.61 Million | 1.066x | -49.67% |
| 2019-12-31 | $-6.18 Million | $-13.09 Million | 2.117x | -40.46% |
| 2018-12-31 | $-19.41 Million | $-69.03 Million | 3.556x | -- |
About Connect Biopharma Holdings Ltd
Connect Biopharma Holdings Limited operates as a clinical-stage biopharmaceutical company in the United States. It develops rademikibart, a human monoclonal IgG4 antibody directed against IL-4Ra in two Phase 2 trials for the treatment of acute exacerbations of asthma and chronic obstructive pulmonary disease (COPD). The company was founded in 2012 and is headquartered in San Diego, California.